GoodRx Holdings, Inc. (GDRX) Q1 2026 Earnings Call Transcript

GoodRx Holdings, Inc. (GDRX) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 8, 2026

Big Pharma Runs Its Checkout Counter Through GoodRx

Out-of-pocket drug costs are rising for millions of Americans. Coverage gaps are widening.

PYMNTS • May 7, 2026

Should You Add OPRX Stock to Your Portfolio Pre-Q1 Earnings?

OptimizeRx nears Q1 earnings amid declining revenue forecasts, softer trends and a cautious outlook, raising questions on near-term upside.

Zacks Investment Research • May 7, 2026

GoodRx Reports First Quarter 2026 Results

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2026. First Quarter 2026 Highlights Revenue of $194.0 million Net income of $1.2 million; Net income margin of 0.6% Adjusted Net Income1 of $23.0 million; Adjusted Net Income Margin1 of 11.9% Adjusted EBITDA1 of $58.3 million; Adjusted EBITDA Margin1 of 30.

Business Wire • May 6, 2026

GoodRx Holdings, Inc. (GDRX) Q1 Earnings Match Estimates

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.07 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.09 per share a year ago.

Zacks Investment Research • May 6, 2026

GoodRx (GDRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for GoodRx (GDRX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • May 7, 2026

GoodRx Expands Offerings to Now Include Ozempic® Pill for Type 2 Diabetes Patients

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that it is providing access to self-pay pricing for Novo Nordisk's Ozempic® pill (oral semaglutide), helping eligible patients with type 2 diabetes obtain the medication for as low as $149 per month at pharmacies nationwide. “As Novo Nordisk brings the Ozempic pill to market, we're focused on helping patients access it with clear, transparent pricing,” said We.

Business Wire • May 1, 2026

OptimizeRx vs. GoodRx: Which Digital Health Stock is the Better Buy?

OPRX edges past GDRX with AI-driven platform momentum, stronger estimates and lower valuation despite near-term revenue headwinds.

Zacks Investment Research • Apr 24, 2026

GoodRx Announces Date for First Quarter 2026 Earnings Release and Conference Call

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for prescription savings in the U.S., today announced it will release its first quarter 2026 financial results after U.S. markets close on Wednesday, May 6, 2026. GoodRx management will also hold a conference call and webcast the following morning, Thursday, May 7, 2026 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business o.

Business Wire • Apr 17, 2026

GoodRx Rallies As Wegovy HD Rollout Targets Self-Pay Market

• GoodRx Holdings shares are advancing steadily. What's driving GDRX shares up?

Benzinga • Apr 15, 2026